Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Teva Pharmaceutical Industries (TEVJF) Revenue (2016 - 2025)

Teva Pharmaceutical Industries (TEVJF) has disclosed Revenue for 10 consecutive years, with $4.7 billion as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Revenue rose 11.4% year-over-year to $4.7 billion, compared with a TTM value of $17.3 billion through Dec 2025, up 4.32%, and an annual FY2025 reading of $17.3 billion, up 4.32% over the prior year.
  • Revenue was $4.7 billion for Q4 2025 at Teva Pharmaceutical Industries, up from $4.5 billion in the prior quarter.
  • Across five years, Revenue topped out at $4.7 billion in Q4 2025 and bottomed at $3.6 billion in Q3 2022.
  • Average Revenue over 5 years is $4.0 billion, with a median of $3.9 billion recorded in 2021.
  • The sharpest move saw Revenue fell 8.61% in 2021, then grew 14.75% in 2023.
  • Year by year, Revenue stood at $4.1 billion in 2021, then fell by 5.27% to $3.9 billion in 2022, then increased by 14.75% to $4.5 billion in 2023, then decreased by 5.12% to $4.2 billion in 2024, then grew by 11.4% to $4.7 billion in 2025.
  • Business Quant data shows Revenue for TEVJF at $4.7 billion in Q4 2025, $4.5 billion in Q3 2025, and $4.2 billion in Q2 2025.